• Alias: PXD101
    • A novel hydroxamic acid-type HDAC inhibitor that targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis
    • FDA approved for relapsed, refractory, PTCL
    • Recommended dose: 1,000 mg/m2 IV over 30 minutes on days 1 to 5 every 21 days until disease progression. NOTE: If the patient is homozygous for UGT1A1*28 allele, reduce the initial dose to 750 mg/m 2.
    • Half-life: 1.1 hours
    • Side effects: Peripheral edema, prolonged QT, fatigue, chills, headache, rash, pruritus, hypokalemia, anemia, thrombocytopenia, dyspnea, fevers, hypotension, elevated SCr
    Other topics in Targeted and Immunotherapy Agents